Cabozantinib Updates

CheckMate 9ER trial involves following Arms

• Nivolumab plus cabozantinib versus sunitinib in first-line treatment for aRCC
• Nivolumab plus cabozantinib versus sunitinib in third line treatment for aRCC
• Nivolumab plus cabozantinib versus sorafenib in first-line treatment for aRCC
• pembrolizumab plus cabozantinib versus sunitinib in first-line treatment for aRCC

Dose of cabozantinib in combination with Nivolumab in CheckMate_9ER Trial

• 50 mg orally once daily
• 40 mg orally once daily
• 60 mg orally once daily
• 20 mg orally once daily

Updated median progression-free survival of CheckMate 9ER trial of cabozantinib + Nivolumab arm was

• 16·6 months
• 16 months
• 16.9 months
• 17 months

The Primary end point of study CheckMate_9ER trial was

• rPFS
• PFS
• OS
• QOL

Which of the following statement is true for CheckMate_9ER Study

• Is a study of Nivolumab + cabozantinib vs sunitinib in 1L treatment for aRCC
• Patients were randomly assigned (1:2) in two arms
• The extended follow-up was 22·9 months
• All of the above

COSMIC-312 trial involves following Arms

• Cabozantinib plus atezolizumab versus sorafenib for aHCC
• Cabozantinib plus atezolizumab versus sorafenib for aRCC
• Cabozantinib plus pembrolizumab versus sorafenib for aHCC
• Cabozantinib plus axitinib versus sorafenib for aHCC

Median follow-up in COSMIC-312 is

• 14·8 months
• 15·8 months
• 10.8 months
• 19.8 months

Median progression free survival in COSMIC 312 trial in combination arm was

• 7.8 months
• 6·8 months
• 6.5 months
• 5.8 months

Translational randomized --------------- of cabozantinib + nivolumab in advanced, recurrent, or metastatic endometrial cancer

• Phase II trial
• Phase III
• Retrospective
• Phase Ib

In Phase 2 trial of Cabozantinib + nivolumab in advance recurrent or metastatic endometrial cancer randomisation was

• . 1:1
• .3:1
• .1:1:1
• * 2:1